Biotron's COVID-19 series detection reagent successfully obtained the EU CE access certification on   March 21,2020. According to the relevant EU laws and certification procedures, the products comply with  The compliance requirements of the "EU Medical Device Directives" have officially obtained the qualifications to enter the EU market, contributing a "China" force to the global common epidemic.

Meanwhile Biotron used the original single-tube multiple probe amplification technology (MPA) to develop a respiratory pathogen nucleic acid joint detection kit based on the RT-PCR platform, which can simultaneously detect 12 respiratory   viruses (including the new coronavirus, ORF1ab gene) And 15 bacteria. Because of its extremely high specificity and  sensitivity, this technology can screen multiple targets at once, cover common pathogenic pathogens, and it is convenient and  fast to detect. It is recognized by customers!

The combined RVP+RBP reagent can realize the “1+1” comprehensive detection mode for common respiratory pathogens. In the combined detection mode, it can detect 2019-nCoV and 32 other respiratory infection pathogens at the same time, which is the most comprehensive detection reagent at home and abroad. (Except for mNGS), it basically covers clinically common pathogens of respiratory tract infections.